From: Immunotherapeutic interventions of Triple Negative Breast Cancer
Targets/types | Drug | Patient population | Recruitment | Phase | ClinicalTrials. gov ID |
---|---|---|---|---|---|
Clinical trials in the neoadjuvant setting | |||||
 PD-1 | Pembrolizumab | TNBC | Recruiting | II | NCT03145961 |
III | NCT03036488 | ||||
Active, not recruiting | Ib | NCT02622074 | |||
Not yet recruiting | II | NCT03289819 | |||
PDR001 | TNBC | Recruiting | II | NCT02938442 | |
 PD-L1 | Atezolizumab | TNBC | Not yet recruiting | III | NCT03197935 |
Recruiting | III | NCT03281954 | |||
III | NCT02620280 | ||||
II | NCT02530489 | ||||
Durvalumab | TNBC | Recruiting | II | NCT02685059 | |
I/II | NCT02489448 | ||||
 PD-L1, PARP | Atezolizumab, Veliparib | TNBC, BRCA1/2 mutated, other BCs | Recruiting | II | NCT02849496 |
 VEGF-A | Bevacizumab | TNBC | Recruiting | II | NCT02456857 |
 EGFR | Panitumumab | TNBC | Recruiting | II | NCT02593175 |
TN-IBC | Recruiting | II | NCT02876107 | ||
 ACT | DC | BC | Recruiting | I/II | NCT03450044 |
γδ T cells | BC | Recruiting | I/II | NCT03183206 | |
DC-CIK | BC | Active, not recruiting | II | NCT02491697 | |
ROR1 + CAR-T cells | TNBC, BCs, Leukemia, Lymphoma | Recruiting | I | NCT02706392 | |
 Vaccine | DC vaccine | TNBC and other BCs | Recruiting | I/II | NCT02018458 |
Neoantigen DNA | TNBC | Recruiting | I | NCT03199040 | |
PVX-410 | TNBC | Recruiting | I | NCT02826434 | |
Clinical trials in the adjuvant setting | |||||
 PD-1 | Pembrolizumab | TNBC | Recruiting | III | NCT03036488 |
TNBC and other BCs | Recruiting | III | NCT02954874 | ||
 PD-1, PARP | Pembrolizumab, Niraparib | TNBC, OC | Recruiting | I/II | NCT02657889 |
 ACT | NK cells | BC | Recruiting | I/II | NCT02844335 |
DC-CIK | TNBC, HCC, RCC, UBC, CRC, NSCLC | Recruiting | I/II | NCT02886897 | |
 Vaccine | PVX-410 | TNBC | Recruiting | I | NCT02826434 |
Clinical trials in the metastatic setting | |||||
 PD-1 | Pembrolizumab | TNBC | Active, not recruiting | III | NCT02555657 |
II | NCT02447003 | ||||
Recruiting | III | NCT02819518 | |||
II | NCT02768701 | ||||
II | NCT02755272 | ||||
I/II | NCT02734290 | ||||
Ib/II | NCT01676753 | ||||
Not yet recruiting | II | NCT03121352 | |||
TNBC, IBC | Not yet recruiting | II | NCT03184558 | ||
Nivolumab | TNBC | Recruiting | II | NCT03316586 | |
II | NCT02499367 | ||||
JS001 | TNBC | Not yet recruiting | I | NCT03251313 | |
Recruiting | I | NCT03151447 | |||
PDR001 | TNBC, NSCLC, TC, Melanoma | Recruiting | Ib/II | NCT02404441 | |
TNBC, CRC, NSCLC | Recruiting | I | NCT02890069 | ||
 PD-L1 | Atezolizumab | TNBC | Not yet recruiting | II | NCT03164993 |
Active, not recruiting | III | NCT02425891 | |||
Recruiting | III | NCT03125902 | |||
Ib/II | NCT02708680 | ||||
IIb | NCT01898117 | ||||
Durvalumab | TNBC | Recruiting | I/II | NCT02628132 | |
Avelumab | TNBC, SCCHN, SCLC, NSCLC, Melanoma, | Recruiting | Ib/II | NCT02554812 | |
 CTLA-4 | Tremelimumab | TNBC, UBC, PDAC | Active, not recruiting | II | NCT02527434 |
 PD-L1, CTLA-4 | Durvalumab, Tremelimumab | TNBC, SCCHN, SCLC, GEJ, PDAC, ESCC | Recruiting | Ib | NCT02658214 |
 PD-1, PARP | Pembrolizumab, Niraparib | TNBC, OC | Recruiting | I/II | NCT02657889 |
 PD-L1, PARP | Durvalumab, Olaparib | TNBC | Recruiting | II | NCT03167619 |
Durvalumab, Olaparib/Cediranib | TNBC, OC, CRC, NSCLC, SCLC, CRPC | Recruiting | I/II | NCT02484404 | |
Atezolizumab, Veliparib | TNBC, BRCA1/2 mutated, other BCs | Recruiting | II | NCT02849496 | |
 VEGF-A | Bevacizumab | TNBC and other BCs | Active, not recruiting | II | NCT00733408 |
 ACT | NK cells | BC | Recruiting | I/II | NCT02843126 |
Anti-MUC1 CAR-T cells | TNBC, HCC, NSCLC, PC | Recruiting | I/II | NCT02587689 | |
NKG2D CAR-T cells | TNBC, CRC, OC, UC, PC, MM | Recruiting | I/II | NCT03018405 | |
 Vaccine | haNK cell | TNBC | Not yet recruiting | Ib/II | NCT03387085 |
Ib/II | NCT03175666 | ||||
 ADC | IMMU-132 | TNBC | Recruiting | III | NCT02574455 |
Not yet recruiting | II | NCT02161679 | |||
CDX-011 | TNBC | Active, not recruiting | II | NCT01997333 | |
SGN-LIV1A | TNBC | Recruiting | I | NCT01969643 | |
 ADC, PD-1 | SGN-LIV1A, Pembrolizumab | TNBC | Recruiting | Ib/II | NCT03310957 |